Skip to main content

Table 3 Univariate and multivariate analyses for DFS among patients with trastuzumab

From: Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

FactorUnivariateMultivariate p-value
p-valueHR95%CI
Age (≤40 vs. > 40)< 0.0013.9071.551–9.8400.004
T stage0.417   
 (T2 vs. T1)
 (T3 vs. T1)
    
pN stage< 0.001   
 (pN1 vs. pN0) 2.9300.832–10.3200.094
 (pN2–3 vs. pN0) 9.4783.026–29.681< 0.001
Grade (3 vs. 1–2)0.013  0.435
HR (negative vs. positive)0.0015.8541.878–18.2450.002
Ki67 (≥30% vs. < 30%)0.574   
pre-NLR (high vs. low)0.0032.9171.055–8.0620.039
NC (yes vs. no)0.333   
  1. HR, hazard ratio; CI, confidence interval; NC, neoadjuvant chemotherapy; NLR, neutrophil/lymphocyte ratio; ALC, absolute lymphocyte count. Statistically significant factors are in bold font